BioCentury | Nov 17, 2017
Company News

Monopar acquires cancer candidate from Gem, raises $9.7M

...Cancer company Monopar Therapeutics Inc. (Northbrook, Ill.) said it acquired candidates including GPX-150 from Gem Pharmaceuticals LLC (Pelham...
...cancers, according to the filing. Monopar Therapeutics Inc., Northbrook, Ill. Gem Pharmaceuticals LLC, Pelham, Ala. Business: Cancer Allison Johnson GPX-150 Gem Pharmaceuticals LLC Monopar...
BioCentury | Jun 20, 2016
Clinical News

GPX-150: Preliminary Phase II data

...adverse events. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Gem Pharmaceuticals LLC...
BioCentury | Feb 2, 2015
Clinical News

GPX-150: Phase II started

...2 IV GPX-150 every 3 weeks for up to 48 weeks in about 30 patients. Gem Pharmaceuticals LLC...
BioCentury | Jan 15, 2009
Cover Story

(Back)boning up on polyketides

...who might otherwise lack the expertise to access them," he said. Gerald Walsh, CEO of Gem Pharmaceuticals LLC...
...online Jan. 15, 2008 Companies and Institutions Mentioned Coronado Biosciences Inc. , San Diego, Calif. Gem Pharmaceuticals LLC...
BioCentury | Jan 14, 2002
Company News

Access Oncology Inc., Gem Pharm deal

Access licensed from Gem GPX-100 and GPX-150, 2 non-cardiotoxic analogs of doxorubicin, to treat cancer. Gem will receive upfront payments and milestones totaling up to $33 million, plus royalties. Access will be responsible for all...
BioCentury | Jun 7, 1999
Company News

Gem Pharm, Pharming deal

PHAR will receive exclusive worldwide rights to Gem's lactoferrin as a heparin-neutralizing agent in open heart surgery. PHAR and Gem have an ongoing collaboration to develop the product (see BioCentury, Dec. 7, 1998). Gem Pharmaceuticals...
BioCentury | Dec 7, 1998
Company News

Gem Pharm, Pharming Holding N.V. deal

The companies will develop and commercialize human lactoferrin (GPX-400) to replace protamine as a heparin-neutralizing agent in open heart surgery. PHAR will provide Gem with the raw material and Gem will produce the finished drug....
BioCentury | Mar 9, 1998
Company News

Gem Pharm management update

Gem Pharmaceuticals Inc., Birmingham, Ala. Business: Cancer, Cardiovascular Hired: David Walsh as VP of operations, formerly VP of drug development and quality management at BioCryst Pharmaceuticals Inc. WIR Staff...
BioCentury | Mar 2, 1998
Company News

Gem Pharm board of directors update

Gem Pharmaceuticals Inc., Birmingham, Ala. Business: Cancer, Cardiovascular Appointed: Richard Power, executive director of The Sage Group WIR Staff cancer Cardiovascular...
BioCentury | Dec 22, 1997
Company News

Gem Pharm management update

Gem Pharmaceuticals Inc., Birmingham, Ala. Business: Cancer, Cardiovascular Hired: Gerald Walsh as VP of business development, formerly VP of biological sciences at BioCryst Pharmaceuticals Inc. WIR Staff...
Items per page:
1 - 10 of 11
BioCentury | Nov 17, 2017
Company News

Monopar acquires cancer candidate from Gem, raises $9.7M

...Cancer company Monopar Therapeutics Inc. (Northbrook, Ill.) said it acquired candidates including GPX-150 from Gem Pharmaceuticals LLC (Pelham...
...cancers, according to the filing. Monopar Therapeutics Inc., Northbrook, Ill. Gem Pharmaceuticals LLC, Pelham, Ala. Business: Cancer Allison Johnson GPX-150 Gem Pharmaceuticals LLC Monopar...
BioCentury | Jun 20, 2016
Clinical News

GPX-150: Preliminary Phase II data

...adverse events. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Gem Pharmaceuticals LLC...
BioCentury | Feb 2, 2015
Clinical News

GPX-150: Phase II started

...2 IV GPX-150 every 3 weeks for up to 48 weeks in about 30 patients. Gem Pharmaceuticals LLC...
BioCentury | Jan 15, 2009
Cover Story

(Back)boning up on polyketides

...who might otherwise lack the expertise to access them," he said. Gerald Walsh, CEO of Gem Pharmaceuticals LLC...
...online Jan. 15, 2008 Companies and Institutions Mentioned Coronado Biosciences Inc. , San Diego, Calif. Gem Pharmaceuticals LLC...
BioCentury | Jan 14, 2002
Company News

Access Oncology Inc., Gem Pharm deal

Access licensed from Gem GPX-100 and GPX-150, 2 non-cardiotoxic analogs of doxorubicin, to treat cancer. Gem will receive upfront payments and milestones totaling up to $33 million, plus royalties. Access will be responsible for all...
BioCentury | Jun 7, 1999
Company News

Gem Pharm, Pharming deal

PHAR will receive exclusive worldwide rights to Gem's lactoferrin as a heparin-neutralizing agent in open heart surgery. PHAR and Gem have an ongoing collaboration to develop the product (see BioCentury, Dec. 7, 1998). Gem Pharmaceuticals...
BioCentury | Dec 7, 1998
Company News

Gem Pharm, Pharming Holding N.V. deal

The companies will develop and commercialize human lactoferrin (GPX-400) to replace protamine as a heparin-neutralizing agent in open heart surgery. PHAR will provide Gem with the raw material and Gem will produce the finished drug....
BioCentury | Mar 9, 1998
Company News

Gem Pharm management update

Gem Pharmaceuticals Inc., Birmingham, Ala. Business: Cancer, Cardiovascular Hired: David Walsh as VP of operations, formerly VP of drug development and quality management at BioCryst Pharmaceuticals Inc. WIR Staff...
BioCentury | Mar 2, 1998
Company News

Gem Pharm board of directors update

Gem Pharmaceuticals Inc., Birmingham, Ala. Business: Cancer, Cardiovascular Appointed: Richard Power, executive director of The Sage Group WIR Staff cancer Cardiovascular...
BioCentury | Dec 22, 1997
Company News

Gem Pharm management update

Gem Pharmaceuticals Inc., Birmingham, Ala. Business: Cancer, Cardiovascular Hired: Gerald Walsh as VP of business development, formerly VP of biological sciences at BioCryst Pharmaceuticals Inc. WIR Staff...
Items per page:
1 - 10 of 11